Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
91 hedge funds and large institutions have $104M invested in Concert Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 23 reducing their positions, and 30 closing their positions.
150% more call options, than puts
Call options by funds: $604K | Put options by funds: $242K
52% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 23
9% less funds holding
Funds holding: 100 → 91 (-9)
13.22% less ownership
Funds ownership: 77.77% → 64.55% (-13%)
30% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 30
66% less capital invested
Capital invested by funds: $301M → $104M (-$198M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.78M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.48M |
| 3 |
Renaissance Technologies
New York
|
+$2.81M |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
+$2.8M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LC
L1 Capital
Melbourne VIC 3000,
Australia
|
-$14.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.3M |
| 3 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$8.6M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$6.84M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$6.79M |
CNCE Hedge Fund Activity: Q1 2021 in Review
91 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2021, worth a combined $104M — down 66% from $301M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of CNCE and 21 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 35 added.
The largest buyer was RA Capital Management, adding an estimated $9.78M. The largest seller was L1 Capital, exiting entirely with an estimated $14.6M sold.
- 91 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2021, down from 100 in Q4 2020.
- Funds reported $104M of Concert Pharmaceuticals, Inc. stock for Q1 2021, down 66% quarter-over-quarter.
- 21 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2021 and 30 closed out, a net change of -9 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q1 2021 was RA Capital Management, an estimated $9.78M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q1 2021 was L1 Capital, an estimated $14.6M sold.
Based on aggregated 13F filings for Q1 2021.